Great interview with ex-Novartis CEO Daniel Vasella on leadership & the CEO role. As an early investor & board member at Eclipsebio, he’s been a generous mentor. Grateful to receive the same thoughtful guidance—especially on embracing competition and resilience. #rna #biotech
#CEO POV: Daniel Vasella on resilience in @McKinsey's #Leadership21st century interview series: bit.ly/McKNovartisCEO #pharma
Very cool free bioinformatics resource for those studying RNA binding proteins that regulate RNA.
Attention #RNA Researchers! We are excited to introduce our newest Bioinformatics Resource Center including #ENCODE summary reports for your RBP of interest, analyzed & made interactive by Eclipsebio
Let us support you as you navigate the depths of RNA #genomics data, Visit -eclipsebio.com/bioinformatic…
Find additional educational resources like #bioinformatics eBlogs to stay updated with the latest in RNA genomics, and the Lunar™ data analysis portal to help tackle your analysis
Proud of the team for getting these important RNA genomics products into the hands of RNA drug discovery and research scientists to get life-changing medicines to patients, faster.
We are excited to announce the completion of intellectual property licenses related to #RNA structure probing, ribosome occupancy, and RNA modifications.
Read the press release at: eclipsebio.com/eclipsebio-ex…
#Genomics #Biotech #Biotechnology
Thrilled to continue building important RNA genomics tech with our amazing team to enable next-gen RNA therapeutics and vaccines. Big thanks to our new and early seed investors for their unwavering support. eclipsebio.com/eclipsebios-s…
Eclipsebio is growing our commercial group! Top RNA vaccine and RNA tx biopharmas and researchers use our RNA genomics technologies to design tomorrow's RNA medicines. VP commercial, dir bus dev, dir marketing and sales associate opportunities posted: eclipsebio.com/about/careers…
Powerful study highlighting the potential of RNA binding proteins as novel targets in cancer. ~2000 RNA binding proteins at last count ….
Grateful to Yeo lab members and @twestbrooklab for systematically dissecting RNA binding proteins as vulnerabilities in triple-negative breast cancer fiercebiotech.com/research/n…
Peter Chu retweeted
Grateful to Yeo lab members and @twestbrooklab for systematically dissecting RNA binding proteins as vulnerabilities in triple-negative breast cancer fiercebiotech.com/research/n…
Peter Chu retweeted
I recently shared a blog about maintaining a strong culture through periods of growth. One of our values at Dyne is The Dyne Family and as a leader, it’s important to me that we continue to foster the strong culture that our company was built on: bit.ly/2RAZj4V
Peter Chu retweeted
Are you studying #RNA binding protein interactions,
microRNA targets or RNA modifications? Check out the @RNASociety webinar about our powerful technology: the eCLIP platform.
#mRNA #m6A #RBP #eCLIP
youtube.com/watch?v=cXsHF_bp…
The new normal for advancing scientific progress, especially in the RNA world!
@RNAsociety is moving online this year! But this is not going to stop us… Don’t miss out Eclipse Bio's #RNA2020 Webinar: The eCLIP platform: A powerful technology to study RNA binding protein interactions, microRNA targets and RNA modifications More info: bit.ly/2TvmYSe
Peter Chu retweeted
Prep Boys are excited to welcome defensemen Max Chu from San Diego, California for the 2018-2019 season. A two-time California State Champion, Max played last season with the San Diego Gulls 16U AAA program. Welcome Max!
